1445 related articles for article (PubMed ID: 21849682)
1. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
2. Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice.
Kulkarni OP; Ryu M; Kantner C; Sárdy M; Naylor D; Lambert D; Brown R; Anders HJ
Nephrol Dial Transplant; 2012 Apr; 27(4):1358-67. PubMed ID: 21987536
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
4. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
[TBL] [Abstract][Full Text] [Related]
5. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
Faust J; Menke J; Kriegsmann J; Kelley VR; Mayet WJ; Galle PR; Schwarting A
Arthritis Rheum; 2002 Nov; 46(11):3083-95. PubMed ID: 12428253
[TBL] [Abstract][Full Text] [Related]
6. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
[TBL] [Abstract][Full Text] [Related]
8. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
9. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells.
Patole PS; Gröne HJ; Segerer S; Ciubar R; Belemezova E; Henger A; Kretzler M; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 May; 16(5):1326-38. PubMed ID: 15772251
[TBL] [Abstract][Full Text] [Related]
10. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice.
Miyazaki T; Ono M; Qu WM; Zhang MC; Mori S; Nakatsuru S; Nakamura Y; Sawasaki T; Endo Y; Nose M
Eur J Immunol; 2005 May; 35(5):1510-20. PubMed ID: 15832294
[TBL] [Abstract][Full Text] [Related]
11. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
12. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
13. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity.
Chan OT; Madaio MP; Shlomchik MJ
J Immunol; 1999 Oct; 163(7):3592-6. PubMed ID: 10490951
[TBL] [Abstract][Full Text] [Related]
14. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus.
Jimenez-Caliani AJ; Jimenez-Jorge S; Molinero P; Rubio A; Guerrero JM; Osuna C
J Pineal Res; 2008 Sep; 45(2):204-11. PubMed ID: 18507713
[TBL] [Abstract][Full Text] [Related]
15. Effect of combining ACE inhibitor and statin in lupus-prone mice.
Shimazu H; Kinoshita K; Hino S; Yano T; Kishimoto K; Nagare Y; Nozaki Y; Sugiyama M; Ikoma S; Funauchi M
Clin Immunol; 2010 Aug; 136(2):188-96. PubMed ID: 20403731
[TBL] [Abstract][Full Text] [Related]
16. Skin disease is prevented but nephritis is accelerated by multiple pregnancies in autoimmune MRL/LPR mice.
Kökény G; Godó M; Nagy E; Kardos M; Kotsch K; Casalis P; Bodor C; Rosivall L; Volk HD; Zenclussen AC; Hamar P
Lupus; 2007; 16(7):465-77. PubMed ID: 17670844
[TBL] [Abstract][Full Text] [Related]
17. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
18. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
Zhai ZF; Zhou CL; Zhong BY; Ao JH; Hao F
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):406-10. PubMed ID: 18581896
[TBL] [Abstract][Full Text] [Related]
19. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
20. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
Kulkarni O; Eulberg D; Selve N; Zöllner S; Allam R; Pawar RD; Pfeiffer S; Segerer S; Klussmann S; Anders HJ
J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
